Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2025)

Crinetics Pharmaceuticals has reported Receivables over the past 2 years, most recently at $8.4 million for Q4 2025.

  • Quarterly results put Receivables at $8.4 million for Q4 2025, changed 0.48% from a year ago — trailing twelve months through Dec 2025 was $8.4 million (changed 0.48% YoY), and the annual figure for FY2025 was $8.4 million, changed 0.48%.
  • Receivables for Q4 2025 was $8.4 million at Crinetics Pharmaceuticals, roughly flat from $8.3 million in the prior quarter.
  • Over the last five years, Receivables for CRNX hit a ceiling of $8.4 million in Q4 2025 and a floor of $8.3 million in Q4 2024.